^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    Immunosuppressant

    Related drugs:
    1d
    KOURAGE: A Study of Auxora in Patients With AKI and Injurious Lung "Crosstalk" (clinicaltrials.gov)
    P2, N=150, Active, not recruiting, CalciMedica, Inc. | Recruiting --> Active, not recruiting
    Enrollment closed
    3d
    TREAT-OMG: TheRapeutic Effect of Different immunosuppressAnts on Non-Thymoma Ocular Myasthenia Gravis: a Real-world Study (clinicaltrials.gov)
    P=N/A, N=200, Recruiting, Tang-Du Hospital | Trial completion date: Nov 2024 --> Jun 2026 | Trial primary completion date: Nov 2024 --> Apr 2026
    Trial completion date • Trial primary completion date • Real-world evidence
    |
    prednisone
    3d
    Azathioprine combined with either rifaximin (A microecological inhibitor) or infliximab for inflammatory bowel disease: Differential impacts on intestinal barrier function, inflammatory response and stress injury. (PubMed, Pak J Pharm Sci)
    IFX + AZA for rapid induction remission and RIF+AZA for maintenance therapy in IBD.
    Clinical • Journal
    |
    IL6 (Interleukin 6) • EGF (Epidermal growth factor) • TGFB1 (Transforming Growth Factor Beta 1)
    4d
    The efficacy and safety of Tofacitinib combined with mycophenolate mofetil versus tofacitinib in patients with glucocorticoid resistant ICIs-related myocarditis: a multicenter, randomized, controlled clinical study (ChiCTR2500114368)
    P=N/A, N=116, Not yet recruiting, Zhongshan Hospital, Fudan University; Zhongshan Hospital, Fudan University
    New trial
    |
    tofacitinib
    5d
    A Two Step Approach to Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Hematologic Malignancies-Increasing GVT Effects Without Increasing Toxicity (clinicaltrials.gov)
    P2, N=51, Completed, Sidney Kimmel Cancer Center at Thomas Jefferson University | Active, not recruiting --> Completed
    Trial completion
    |
    cyclophosphamide
    7d
    Immune Checkpoint Inhibitor-Associated Myocarditis: Risk, Diagnosis, and Clinical Impact. (PubMed, J Clin Med)
    For steroid-refractory cases, second-line options include mycophenolate mofetil (MMF), intravenous immunoglobulin (IVIG), and emerging therapies like abatacept and ruxolitinib. ICI-M is a rare yet highly lethal cardiac complication demanding high clinical vigilance and timely diagnosis. Management hinges on an aggressive multidisciplinary approach, aiming to minimize toxicity while balancing oncological efficacy.
    Review • Journal • Checkpoint inhibition • IO biomarker
    |
    CD8 (cluster of differentiation 8)
    |
    Jakafi (ruxolitinib)
    8d
    CSAGCD: Comparison of Conjunctival Goblet Cell Density in Dry Eye Patients Treated With Cyclosporine 0.1% Dissolved in Perfluorobutylpentane (Vevye®) or Generic 0.05% Cyclosporine Emulsion for 8 Weeks (clinicaltrials.gov)
    P4, N=60, Not yet recruiting, Baylor College of Medicine
    New P4 trial
    9d
    Study of HLA-Haploidentical Stem Cell Transplantation to Treat Clinically Aggressive Sickle Cell Disease (clinicaltrials.gov)
    P2, N=50, Recruiting, University of Illinois at Chicago | Trial completion date: Nov 2025 --> May 2026 | Trial primary completion date: Nov 2025 --> May 2026
    Trial completion date • Trial primary completion date
    |
    HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1)
    |
    cyclophosphamide • sirolimus • fludarabine IV
    11d
    Uterine Transplantation and Pregnancy Induction in Women Affected by Absolute Uterine Infertility (clinicaltrials.gov)
    P=N/A, N=20, Recruiting, Baylor Research Institute | Active, not recruiting --> Recruiting | Trial completion date: Jan 2026 --> Nov 2026 | Trial primary completion date: Jan 2023 --> Nov 2026
    Enrollment open • Trial completion date • Trial primary completion date
    12d
    A Randomized Multicenter Study for Isolated Skin Vasculitis (clinicaltrials.gov)
    P2, N=90, Recruiting, University of Pennsylvania | Trial completion date: Dec 2025 --> Dec 2028 | Trial primary completion date: Dec 2025 --> Dec 2028
    Trial completion date • Trial primary completion date
    14d
    Targeted Dose Study of ATG in Haploidentical Hematopoietic Stem Cell Transplantation (clinicaltrials.gov)
    P3, N=204, Completed, Chinese PLA General Hospital | Phase classification: P4 --> P3
    Phase classification
    15d
    Pharmacogenomics of Thiopurine Drugs: A Bench-To-Bedside Success Story in Thailand. (PubMed, Clin Transl Sci)
    However, the composite effects of these genetic variants remain unexplored at the global scale. Proper large-scale studies with multi-ethnic patients can provide a clear understanding of the TPMT/NUDT15 association and would pave the way towards the optimization of thiopurine drugs to achieve precision medicine.
    Review • Journal
    |
    NUDT15 (Nudix Hydrolase 15)
    |
    mercaptopurine